
Mesoblast (MESO) Stock Forecast & Price Target
Mesoblast (MESO) Analyst Ratings
Bulls say
Mesoblast Ltd has demonstrated significant growth potential, with projected revenues from Ryoncil expected to increase from $24 million in 2025 to $368 million by 2032. The company’s enhanced enterprise value is now estimated at $3.16 billion, reflecting a substantial increase from previous valuations, driven by the potential of its therapies and international partnerships. Additionally, the promising clinical outcomes of Ryoncil, showing improved survival rates compared to available therapies, and the increase in valuation for multiple product candidates further support a positive outlook for the company's financial performance.
Bears say
Mesoblast Ltd faces significant challenges that contribute to a negative outlook for its stock. The company's reliance on JCR for TEMCELL sales may result in lower-than-expected royalty revenues, compounded by clinical trial risks that could negatively impact product approval timelines and success rates. Additionally, the potential inadequacies in safety and efficacy profiles, as highlighted by recent adverse event data and regulatory hurdles, further diminish confidence in the company’s ability to achieve its commercialization goals.
This aggregate rating is based on analysts' research of Mesoblast and is not a guaranteed prediction by Public.com or investment advice.
Mesoblast (MESO) Analyst Forecast & Price Prediction
Start investing in Mesoblast (MESO)
Order type
Buy in
Order amount
Est. shares
0 shares